Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,667Revenue $M13.9Net Margin (%)-235.2Z-Score7.3
Enterprise Value $M2,577EPS $-1.2Operating Margin %-143.2F-Score0
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-241.6Higher ROA y-yN
Price/Book7.410-y EBITDA Growth Rate %0Quick Ratio4.2Cash flow > EarningsN
Price/Sales55.35-y EBITDA Growth Rate %0Current Ratio4.6Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-22.3Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-29.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M101ROI % (ttm)-110.7Gross Margin Increase y-yN

Gurus Latest Trades with XON

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
XONDavid Einhorn 2014-09-30 Reduce-0.06%$17.86 - $26.59
($21.29)
$ 26.5325%Reduce -47.39%197,278
XONJean-Marie Eveillard 2014-06-30 Buy 0.04%$15.3 - $25.93
($21.15)
$ 26.5325%New holding, 661564 sh.661,564
XONDavid Einhorn 2014-06-30 Reduce-0.39%$15.3 - $25.93
($21.15)
$ 26.5325%Reduce -72.81%375,000
XONDaniel Loeb 2014-03-31 Add0.18%$22.5 - $36.82
($28.82)
$ 26.53-8%Add 18.15%3,000,000
XONDavid Einhorn 2014-03-31 Reduce-0.26%$22.5 - $36.82
($28.82)
$ 26.53-8%Reduce -37.58%1,379,014
XONDaniel Loeb 2013-12-31 Add0.15%$17.65 - $25.5
($21.05)
$ 26.5326%Add 18.07%2,539,200
XONDaniel Loeb 2013-09-30 Buy 1.2%$21.36 - $29.7
($24.16)
$ 26.5310%New holding, 2150592 sh.2,150,592
XONDavid Einhorn 2013-09-30 Buy 0.86%$21.36 - $29.7
($24.16)
$ 26.5310%New holding, 2176868 sh.2,176,868
XONT Boone Pickens 2013-09-30 Buy 0.47%$21.36 - $29.7
($24.16)
$ 26.5310%New holding, 12000 sh.12,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

XON is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
XON Jean-Marie Eveillard 2014-09-30790,3640.790.04+19.47%
XON Daniel Loeb 2014-09-302,900,0002.880.62
XON David Einhorn 2014-09-30197,2780.20.05-47.39%
XON T Boone Pickens 2013-09-3012,0000.010.47New Buy
Premium Most recent portfolio changes are included for Premium Members only!


XON: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KIRK RANDAL JCEO, 10% Owner 2014-05-13Buy65,173$15.1974.65view
Reed Thomas D.Chief Science Officer 2014-05-13Buy640$15.670.06view
Lehr Donald P.Chief Legal Officer 2014-05-13Buy1,850$15.9965.92view
Huang KellySVP-Consumer Sector 2014-05-09Buy3,200$15.7868.12view
Kasser Thomas R.SVP--Food Sector 2014-05-09Buy10,000$13.3998.13view
Krishnan Krish SCOO 2014-05-09Buy20,900$14.2186.7view
Krishnan SumaSVP--Product Development 2014-05-09Buy20,900$14.2186.7view
KIRK RANDAL JCEO, 10% Owner 2014-05-09Buy67,333$15.1675view
KIRK RANDAL JCEO, 10% Owner 2014-03-27Buy243,001$25.723.15view
Frost Gregory IanSVP--Health Sector 2014-03-04Buy100,000$25.952.24view

Press Releases about XON :

    Quarterly/Annual Reports about XON:

    News about XON:

    Articles On GuruFocus.com
    5-Year Lows: American Eagle Outfitters, Intrexon Corp, Mack-Cali Realty Corp, and Weight Watchers In Apr 20 2014 
    Daniel Loeb Comments on Intrexon Corporation Jan 22 2014 
    Daniel Loeb Lags S&P But Top New Stocks Advance Jan 07 2014 
    David Einhorn’s New Stocks – TPX, XON, NVR Nov 14 2013 
    Weekly CEO Buys Highlight: XON, ARCP, FSFR, CNTY, RHP Aug 18 2013 

    More From Other Websites
    Biotech Bull Markets and Billion-Dollar Valuations Dec 23 2014
    Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the... Dec 22 2014
    Jim Cramer's Top Stock Picks: DRI XON PII Dec 13 2014
    Putin urges to develop Russian science to fend off sanctions Dec 08 2014
    Intrexon Announces the Appointment of Peter Emtage, Ph.D., as Vice President, Synthetic Immunology Dec 04 2014
    Intrexon Announces the Appointment of Peter Emtage, Ph.D., as Vice President, Synthetic Immunology Dec 04 2014
    ZIOPHARM and Intrexon Present Clinical and Preclinical Data From Immuno-Oncology Programs at AACR... Dec 03 2014
    ZIOPHARM and Intrexon Present Clinical and Preclinical Data From Immuno-Oncology Programs at AACR... Dec 03 2014
    ZIOPHARM and Intrexon Present Clinical and Preclinical Data From Immuno-Oncology Programs at AACR... Dec 03 2014
    Synthetic Biologics Announces First Patient Dosed in Phase 1a Clinical Trial of SYN-004 for the... Dec 02 2014
    BioPop Offers Bioluminescent Dino Pet Gift Option for Holiday Gifting Nov 26 2014
    INTREXON CORP Financials Nov 21 2014
    Can the Rally in Intrexon (XON) Shares Continue? Nov 19 2014
    Fibrocell Science Announces IND Allowed to Proceed to Develop New Treatment for Wounded Warrior... Nov 18 2014
    Intrexon Announces Third Quarter 2014 Financial Results Nov 13 2014
    INTREXON CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 13 2014
    Intrexon Announces Third Quarter 2014 Financial Results Nov 13 2014
    Q3 2014 Intrexon Corp Earnings Release - After Market Close Nov 13 2014
    ROI Land Investments Ltd. Closes $6,000,000 Equity Investment Nov 12 2014
    ROI Land Investments Ltd. Closes $6,000,000 Equity Investment Nov 12 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK